The cardiovascular dysmetabolic syndrome

American Journal of Medicine

Volumn 105, Issue 1 A, 1998, Pages 77S-82S

  Fagan, Timothy C ^a   Deedwania, Prakash C ^b,c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONFERENCE PAPER; CORONARY RISK; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SYNDROME DELINEATION; SYNDROME X;

EID: 0032490706     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00216-2     Document Type: Conference Paper

References (57)

1. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
2. Sowers J.R. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med. 158:1998;617-621.
3. Hsueh W.A., Law R.E. Cardiovascular risk continuum implications of insulin resistance and diabetes . Am J Med. 105:(suppl 1A):1998;4S-14S.
4. Nabulsi A.A., Folsom A.R., Heiss G., et al. Fasting hyperinsulinemia and cardiovascular disease risk factors in nondiabetic adults stronger associations in lean versus obese subjects . Metabolism. 44:1995;914-922.
5. Haffner S.M., Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med. 103:1997;152-162.
6. King G.L., Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am. 25:1996;255-270.
7. Peters A.L., Schriger D.L. The new diagnostic criteria for diabetes the impact on management of diabetes and macrovascular risk factors . Am J Med. 105:(suppl 1A):1998;15S-19S.
8. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 20:1997;1183-1197.
9. Harris M.I., Hadden W.C., Knowler W.C., Bennett P.H. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes. 36:1987;523-534.
10. Engelgau M.M., Aubert R.E., Thompson T.J., Herman W.H. Screening for NIDDM in nonpregnant adults a review of principles, screening tests, and recommendations . Diabetes. 18:1995;1606-1618.
11. Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin-dependent diabetes. In: Harris MI, ed. Diabetes in America. 2nd ed. Washington, DC: National Institutes of Health; 1995:47-67. National Institute of Diabetes and Digestive and Kidney Diseases NIH publication 95-1468.
12. Harris M.I. Impaired glucose tolerance in the U.S. population. Diabetes Care. 12:1989;100-103.
13. Henry R.R. Type 2 diabetes care the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention . Am J Med. 105:(suppl 1A):1998;20S-26S.
14. Joubert P.H., Venter H.L., Foukardis G.N. The effect of miglitol and acarbose after an oral glucose load a novel hypoglycaemic mechanism? Br J Clin Pharmacol. 30:1990;391-396.
15. Stumvoll M., Nurjhan N., Perriello G., et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 333:1995;550-554.
16. Phillips P.J., Scicchitano R., Clarkson A.R., et al. Metformin associated lactic acidosis. Aust N Z J Med. 8:1978;281-284.
17. Ciaraldi T.P., Huber-Knudsen K., Hickman M., Olefsky J.M. Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metabolism. 44:1995;976-982.
18. Fujiwara T., Okuno A., Yoshioka S. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism. 44:1995;486-490.
19. Law R.E., Meehan W.P., Xi X.-P., et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 98:1996;1897-1905.
20. Ghazzi M.N., Perez J.E., Antonucci T.K., et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes. 46:1997;433-439.
21. Henry R.R. Thiazolidinediones. Endocrinol Met Clin North Am. 26:1997;553-573.
22. Suter S.L., Nolan J.J., Wallace P., et al. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 15:1992;193-203.
23. Watkins P.B., Whitcomb R.W. Hepatic dysfunction associated with troglitazone. (letter) N Engl J Med. 338:1998;916-917.
24. Effects of enalapril on mortality in severe congestive heart failure results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med. 316:1987;1429-1435.
25. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
26. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;685-691.
27. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction results of the Survival and Ventricular Enlargement Trial . N Engl J Med. 327:1992;669-677.
28. Lewis E.J., Hunsicker L.G., Bain R.P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 329:1993;1456-1462.
29. Ravid M., Ravid D. ACE inhibitors in elderly patients with hypertension special considerations . Drugs Aging. 8:1996;29-37.
30. Maschio G., Alberti D., Janin G., et al. Effect of angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 334:1996;939-945.
31. Giatras I., Lau J., Levey A.S. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease a meta-analysis of randomized trials . Ann Intern Med. 127:1997;337-345.
32. Quyyumi A.A. Endothelial function in health and disease new insights into the genesis of cardiovascular disease . Am J Med. 105:(suppl 1A):1998;32S-39S.
33. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet. 344:1994;793-795.
34. Parmley W.W. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. Am J Med. 105:(suppl 1A):1998;27S-31S.
35. Chobanian A.V., Haudenschild C.C., Nickerson C., Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 15:1990;327-331.
36. Finta K.M., Fischer M.J., Lee L., et al. Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet. Atherosclerosis. 100:1993;149-156.
37. Mancini G.B.J., Henry G.C., Macaya C., et al. Angiotensin- converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease the TREND (Trial on Reversing ENdothelial Dysfunction) Study . Circulation. 94:1996;258-265.
38. Mancini G.B.J. Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease. Am J Med. 105:(suppl 1A):1998;40S-47S.
39. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease four prospective American studies . Circulation. 79:1989;8-15.
40. Criqui M.H., Golomb B.A. Epidemiologic aspects of lipid abnormalities. Am J Med. 105:(suppl 1A):1998;48S-57S.
41. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high- density lipoprotein cholesterol level a meta-analysis of population-based prospective studies . J Cardiovasc Risk. 3:1996;213-219.
42. Krauss R.M. Triglycerides and atherogenic lipoproteins rationale for lipid management . Am J Med. 105:(suppl 1A):1998;58S-62S.
43. Reaven G.M. Syndrome X 6 years later . J Intern Med. 236:(suppl 736):1994;13-22.
44. Krauss R.M. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol. 5:1994;339-349.
45. Kinosian B., Glick H., Preiss L., Puder K.L. Cholesterol and coronary heart disease predicting risks in men by changes in levels and ratios . J Invest Med. 43:1995;443-450.
46. White C.W. Benefit of aggressive lipid-lowering therapy insights from the Post Coronary Artery Bypass Graft Study and other trials . Am J Med. 105:(suppl 1A):1998;63S-68S.
47. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
48. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
49. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 336:1997;153-162.
50. Heart and Stroke Facts: 1997 Statistical Supplement. Dallas, TX: American Heart Association; 1997.
51. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
52. Amsterdam E.A., Deedwania P. A perspective on hyperlipidemia concepts of management in the prevention of coronary artery disease . Am J Med. 105:(suppl 1A):1998;69S-74S.
53. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 157:1997;2413-2446.
54. Curb J.D., Pressel S.L., Cutler J.A., et al. Effect of diuretic- based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 276:1996;1886-1892.
55. Goldberg R., Sacks F., Howard B., et al. Diabetic response to pravastatin during the CARE Study. (Abstr.) Circulation. 94:(suppl I):1996;I-540.
56. Koskinen P., Mänttäri M., Manninen V., et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 15:1992;820-825.
57. Pyörälä K., Olsson A.G., Pedersen T.R., et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) . Diabetes Care. 20:1997;614-620.